Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
about
Systemic therapy of Cushing's syndromeTreatment of Cushing disease: overview and recent findingsACTH Antagonists60 YEARS OF POMC: Biosynthesis, trafficking, and secretion of pro-opiomelanocortin-derived peptidesCushing's diseaseClinical use of pasireotide for Cushing's disease in adultsThe Treatment of Cushing's Disease.Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegalyCushing's disease: a multidisciplinary overview of the clinical features, diagnosis, and treatmentTranslocator protein-mediated pharmacology of cholesterol transport and steroidogenesisPostoperative testing to predict recurrent Cushing disease in children.Double, synchronous pituitary adenomas causing acromegaly and Cushing's disease. A case report and review of literature.Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.Medical treatment of Cushing's disease: Overview and recent findings.Delayed remission after transsphenoidal surgery in patients with Cushing's disease.Update on medical treatment for Cushing's disease.Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumorsA rare case of an ACTH/CRH co-secreting midgut neuroendocrine tumor mimicking Cushing's diseaseExtended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.Retrospective Analysis of Cushing's Disease with or without HyperprolactinemiaAdvances in understanding pituitary tumorsImpact and timing of bilateral adrenalectomy for refractory adrenocorticotropic hormone-dependent Cushing’s syndromeAldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects.Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitorSelective Glucocorticoid Receptor (GR-II) Antagonist Reduces Body Weight Gain in MiceRecurrent gain-of-function USP8 mutations in Cushing's disease.Clinical Guidelines for the Diagnosis and Treatment of Cushing's Disease in Korea.Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.Endocrine hypertension - Cushing's syndrome.Preoperative Lateralization Modalities for Cushing Disease: Is Dynamic Magnetic Resonance Imaging or Cavernous Sinus Sampling More Predictive of Intraoperative Findings?Treatment Options in Cushing's Disease.Low immediate postoperative serum-cortisol nadir predicts the short-term, but not long-term, remission after pituitary surgery for Cushing's disease.Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extensionEndoscopic bilateral adrenalectomy in patients with ectopic Cushing's syndrome.Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI.Medical management of functioning pituitary adenoma: an update.
P2860
Q22000607-01DBAD4D-7EA5-4A54-A49C-C2D4BA496400Q24626819-ADF509AA-1512-4F6D-9B12-95238E4322A9Q26740152-A314E6CB-0078-4A4A-8F2A-29EB09ECF2F6Q26765954-E14261D4-D275-4CF0-9AE7-1CF1F771827BQ26827386-87155AA1-8BF0-4B70-B7FC-7F494B1B8D29Q26858933-F3FF681F-0D3E-49BE-82E7-F1D38E3CCE86Q27010590-D421E6E7-1E9C-4AA0-98C3-8E914D403E6CQ28069603-801167D0-D632-47DF-94FD-3883AF8D361DQ28071635-14BDE1EB-21E5-4626-BCD6-A32E2608A5DFQ28083751-647DD296-CC93-4863-96D3-E563E4595871Q30435318-99DE428A-B5E6-4159-851A-F472999D85E7Q30604166-26308076-B234-431F-B3F7-51E1D0BF03ABQ33163578-9B0357B2-AAAE-48C5-AF7E-61FB02CE49F0Q33570330-2852ED22-2EC6-40B8-821C-898B4DCF14BAQ33579615-BC9F21CE-AB37-4079-9709-762992E95590Q33735039-5E903A90-2985-4211-BAB8-FBC441F5A2B3Q33736170-B63557A1-2AA8-4821-B274-D7BE6FDB3D96Q33802284-6812029C-BE47-4B5E-B2DE-79B286A4DC16Q33820159-B448FD21-41F4-4E91-9319-8C909827B9CAQ33846182-32A01411-CB2C-428A-A776-00D1029E9F5CQ33858344-E0E4FCDF-5140-4809-863F-1BFF0ACAB058Q33930728-7071D9E3-871A-4734-8F46-EC77733127B0Q34652203-48B9110E-5CBE-4EDB-B35E-5262B622704FQ34660143-CAC0D642-C1D8-4DAE-8275-EA887F348B9FQ34743189-D1EBC58F-E896-411F-9FE8-0A8918C27171Q34995025-B22EC82A-9872-4C27-AB66-CADB8E800563Q35002806-D2AF1ADA-BB35-4FBC-AC8E-D1CF4D12172EQ35137737-010EF07F-2177-41F7-8A49-DF0BA11D0A65Q35146226-F88ADDEB-A92E-43F8-8A9E-79597BF7C6F1Q35260959-0AADE3B8-5222-4F4E-BF26-7DE3435A31E5Q35441693-F0EBA2EF-A6C5-428A-B010-E0B4F920318CQ35578652-4406A197-90DF-49AD-96CE-7A4001F46A7AQ35590898-24586BA3-3F28-4829-9093-0F1CD54135B5Q35611261-40E3DAB7-A64E-4720-9248-42BBF018399FQ35740882-86AA564A-EF5C-472B-93F3-B2FD92C65FEBQ35820698-65C5EFFC-5689-4B11-8376-B7DCC28ECDFBQ35823679-5D64D549-90B4-4A94-9704-0F26CEF4F337Q35848481-9AE10C38-94DA-4804-8A02-8EA85B8B8C59Q35921369-90D088AF-040F-463E-8DFA-0CBE655B9DEEQ35943493-2C8826FC-5420-493B-9820-4A69B214CD6C
P2860
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement
@nl
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
@ast
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
@en
type
label
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement
@nl
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
@ast
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
@en
prefLabel
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement
@nl
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
@ast
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
@en
P2093
P2860
P3181
P356
P1476
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
@en
P2093
A B Grossman
A Klibanski
A R Hermus
B M K Biller
B Swearingen
G K Stalla
J A H Wass
J Bertherat
J Newell-Price
P2860
P304
P3181
P356
10.1210/JC.2007-2734
P407
P577
2008-04-15T00:00:00Z